ALLHAT, or the soft science of the secondary end point.
作者信息
Neely David B
出版信息
Ann Intern Med. 2004 Jul 6;141(1):77. doi: 10.7326/0003-4819-141-1-200407060-00023.
Abstract
摘要
相似文献
1
ALLHAT, or the soft science of the secondary end point.
Ann Intern Med. 2004 Jul 6;141(1):77. doi: 10.7326/0003-4819-141-1-200407060-00023.
2
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications.
Hypertension. 2003 May;41(5):1006-9. doi: 10.1161/01.HYP.0000070905.09395.F6. Epub 2003 Apr 14.
3
ALLHAT: setting the record straight.
Ann Intern Med. 2004 Jul 6;141(1):39-46. doi: 10.7326/0003-4819-141-1-200407060-00013.
4
[ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
Nihon Rinsho. 2001 Mar;59 Suppl 3:393-7.
5
ALLHAT and beyond.
Am J Hypertens. 2003 Jun;16(6):512-4. doi: 10.1016/s0895-7061(03)00856-2.
6
ALLHAT, or the soft science of the secondary end point.
Ann Intern Med. 2003 Nov 4;139(9):777-80. doi: 10.7326/0003-4819-139-9-200311040-00012.
7
ALLHAT and AFFIRM.
Prev Cardiol. 2003 Winter;6(1):54-60. doi: 10.1111/j.1520-037x.2002.2254.x.
8
Comments on the renal aspects of the ALLHAT study.
J Hypertens. 2003 Feb;21(2):235-6. doi: 10.1097/00004872-200302000-00005.
9
Commentary: The ALLHAT Study: implications for the management of resistant hypertension.
J Clin Hypertens (Greenwich). 2005 Jan;7(1):31-2. doi: 10.1111/j.1524-6175.2005.04302.x.
10
ALLHAT: definitive answers or continuing uncertainty?
J Renin Angiotensin Aldosterone Syst. 2003 Mar;4(1):3-5. doi: 10.3317/jraas.2003.004.
Zotero 插件